Search
Strychnine
go.drugbank.com/drugs/DB15954ExperimentalCategories: Compounds used in a research, industrial, or household settingIndocyanine green
go.drugbank.com/drugs/DB16024ApprovedInvestigationalWithdrawnCategories: Compounds used in a research, industrial, or household settingPlixorafenib
go.drugbank.com/drugs/DB16038InvestigationalPLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Cipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigationalGABA-A receptors, similar to the previously approved [propofol]. … Cipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalSepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Synonyms: L-sepiapterinMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.
Bromopyruvate
go.drugbank.com/drugs/DB17135ExperimentalCategories: Compounds used in a research, industrial, or household settingCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory